909 research outputs found
Lionel Barrymore Collection - Accession 1716 M828 (885)
No full textThis collection consists of a framed watercolor painting titled, “Holiday Time in the South” by Lionel Barrymore. The nameplate states: “Painted And Presented To The Citizens Of Rock Hill As A Memento Of My Sincere Appreciation For Their Good Will Towards Me, 8-11-’53, Lionel Barrymore.” Also included in the collection are several photocopies of newspaper articles related to the receipt of the painting from 1953-1954 and a letter written by Lionel Barrymore on his letterhead to Miss Nan Weller Carson of the Rock Hill Public Library dated May 2, 1954. Lionel Barrymore (1878-1954) was a famous actor, director, author, and painter. A member of the Keystone Club of Rock Hill, Mrs. Eva M. White, wrote to Lionel as part of a project she was working on and Mr. Barrymore responded with a letter and telegram. In response, members of the Keystone Club sent several hundred letters and birthday cards to him for his 75th birthday. In thanks he painted and dedicated the watercolor, “Holiday Time in the South” to the City of Rock Hill.https://digitalcommons.winthrop.edu/manuscriptcollection_findingaids/2684/thumbnail.jp
A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody‐Mediated Rejection
No full textABSTRACT Background Antibody‐mediated rejection (ABMR) poses a barrier to long‐term graft survival and is one of the most challenging events after kidney transplantation. Removing donor specific antibodies (DSA) through therapeutic plasma exchange (PLEX) is a cornerstone of antibody depletion but has inconsistent effects. Imlifidase is a treatment currently utilized for desensitization with near‐complete inactivation of DSA both in the intra‐ and extravascular space. Methods This was a 6‐month, randomized, open‐label, multicenter, multinational trial conducted at 14 transplant centers. Thirty patients were randomized to either imlifidase or PLEX treatment. The primary endpoint was reduction in DSA level during the 5 days following the start of treatment. Results Despite considerable heterogeneity in the trial population, DSA reduction as defined by the primary endpoint was 97% for imlifidase compared to 42% for PLEX. Additionally, imlifidase reduced DSA to noncomplement fixing levels, whereas PLEX failed to do so. After antibody rebound in the imlifidase arm (circa days 6–12), both arms had similar reductions in DSA. Five allograft losses occurred during the 6 months following the start of ABMR treatment—four within the imlifidase arm (18 patients treated) and one in the PLEX arm (10 patients treated). In terms of clinical efficacy, the Kaplan–Meier estimated graft survival was 78% for imlifidase and 89% for PLEX, with a slightly higher eGFR in the PLEX arm at the end of the trial. The observed adverse events in the trial were as expected, and there were no apparent differences between the arms. Conclusion Imlifidase was safe and well‐tolerated in the ABMR population. Despite meeting the primary endpoint of maximum DSA reduction compared to PLEX, the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population. Trial Registration EudraCT number: 2018‐000022‐66, 2020‐004777‐49; ClinicalTrials.gov identifier: NCT03897205, NCT0471185
Search-based multi-vulnerability testing of XML injections in web applications (vol 24, pg 3696, 2019): Search-based multi-vulnerability testing of XML injections in web applications (Empirical Software Engineering, (2019), 10.1007/s10664-019-09707-8)
No full textThe article Search-based multi-vulnerability testing of XML injections in web applications, written by Sadeeq Jan, Annibale Panichella, Andrea Arcuri, and Lionel Briand, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on May 2019 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on June 2019 toSoftware Engineerin
Tayler, J. Lionel
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/342115Reference: J. LionelTayler, The Nature of Woman.
Back of card. Author: de Ribera, Paul. Specialty: author.138567
item: [2014.0039.00278] "Tayler, J. Lionel
Prevention of cutaneous cancer recurrences following kidney transplantation: a retrospective comparison of two immunosuppressive strategies based on mTOR inhibitors
No full textLes cancers cutanés, carcinomes spino- et basocellulaires notamment, sont les néoplasies les plus fréquentes après greffe rénale avec un taux élevé de récidives. La conversion d’un anticalcineurines (ACN) vers un agent inhibiteur de mTOR (mammalian target of Rapamycin) est une stratégie qui a fait ses preuves pour réduire les récidives de ses cancers après transplantation rénale. Ce type de conversion étant associé à une incidence de rejet plus important, nous proposons ici un schéma alternatif de prévention de la récidive basé sur une l’association d’un inhibiteur de mTOR à un anticalcineurine à dose réduite. Les récidives de cancers cutanés (hors mélanomes) ont été comparées de façon rétrospective entre deux groupes de patients greffés rénaux, qui avaient moins un cancer cutané : Trente-deux patients ont été convertis à l’Everolimus (EVR), avec une réduction de la posologie de l’anticalcineurine (groupe ACN/EVR), tandis que 43 patients ont été convertis au Sirolimus (SRL) en association à l’acide mycophénolique (AMP) (groupe SRL/AMP). Résultats : La survie sans récidive de cancer cutané à deux ans post-conversion n’était pas différente entre les deux groupes. Dix-sept patients (53.1%) dans le groupe ACN/EVR comparé à 19 (44.2%) dans le groupe SRL/AMP ont développé au moins une lésion cutanée maligne malgré l’introduction de l’inhibiteur de mTOR. L’incidence de rejets était similaire entre les groupes (% vs %, p=). Dans chaque groupe, un seul patient a développé des anticorps antiHLA de novo dirigés contre le donneur (DSA). La moitié des patients de chaque groupe a présenté des effets secondaires, conduisant à l’arrêt de l’inhibiteur de mTOR pour 34% des patients du groupe ACN/EVR contre 16% dans le groupe SRL/AMP (p=0.10). Cette cohorte rétrospective de transplantés rénaux montre qu’un régime immunosuppresseur à base de ACN faible dose/EVR est aussi efficace que l’association SRL/AMP pour réduire l’incidence des récidives de cancers cutanés. Peu de rejet et peu de DSA sont apparus avec les 2 stratégies.Non-melanoma skin cancers (NMSC) are the most frequent malignancies among kidney transplant recipients (KTR) while recurrences are high, partly because of the use of calcineurin inhibitors (CNI). Mammalian target of Rapamycin inhibitors (mTORi) could be an alternative strategy to reduce NMSC recurrences after kidney transplantation, but the effect of an association of a low-dose CNI with a mTORi has not been elucidated. We retrospectively compared NMSC recurrences in two groups of KTR whom immunosuppressive therapy had been adjusted after at least one post-transplant-malignant lesion, with complete or partial conversion from CNI to a mTORi-based regimen. Thirty-two patients were partially converted to Everolimus (EVR) with a reduction of CNI dose (CNI/EVR group), whereas 43 patients were completely converted to Sirolimus (SRL) with continuation of Mycophenolic Acid (MPA) (SRL/MPA group). Results. Two years new NMSC-free survival was not different between the two groups. Seventeen patients (53.1%) in the CNI/EVR group compared to 19 (44.2%) in the SRL/MPA group developed at least one new NMSC despite mTORi conversion (p=0.49). Half of the patients in both groups presented adverse events, leading to mTORi discontinuation for 34% of the CNI/EVR group and 16% of the SRL/MPA group (p=0.10). There was no difference in terms of rejections or emergence of donor specific antibodies (DSA). In a retrospective cohort of KTR, a partial conversion of mTORi with a low-dose CNI is as efficient as a SRL/CNI-free regimen for secondary prevention of skin cancer. Few rejection episodes and few DSA appeared with both strategies
Interview with Ossie Davis, actor, author, producer-director
No full textActor, writer, and director Ossie Davis discusses filmmaking and how African-Americans can and must play a role as not only as actors, but also in technical production so as to ensure the development of films which realistically portray the place of Blacks in contemporary society. Interviewed by Dr. Lionel Barrow and Tejumola Ologeboni.GrayscaleSoun
Les pièges de la narration d'agrément dans Les Confessions de Rousseau
No full textLionel Duisit : the pitfalls of humour in Rousseau's Confessions.
This article, a stylistic approach to Rousseau's Confessions, analyses the tension to be found in the first six books, between Rousseau's concern for self-justification and the ironic tone which he adopts when describing certain incidents of his youth (for example, the stolen ribbon) that would seem to exclude a humorous treatment. Through an analysis of several passages, the author shows how Rousseau's lack of concern for stylistic unity contributes, by the ensuing ambiguity, to psychological veracity.Duisit Lionel. Les pièges de la narration d'agrément dans Les Confessions de Rousseau. In: Dix-huitième Siècle, n°7, 1975. pp. 243-252
Susan Howson, Lionel Robbins
No full textSusan Howson expertly constructs a detailed scholarly biography of Lionel Robbins, the well-known midcentury British economist, from a wealth of source material: not just publications but also diaries, letters, lecture notes, marginalia, and ephemera. There is so much detail in 1161 pages that no reader can reasonably be expected to find every part of it fascinating, although Howson’s writing style is pleasant. The work is neither hagiographical nor critical, the author rarely passing judgmen..
Contributors
No full textFlora Kimmich translates from French and German. Her translation of Gustav Droysen’s monumental nineteenth-century classic History of Alexander the Great [Geschichte Alexanders des Grossen]—the first into English—was published in 2012 by the American Philosophical Society. Lionel Gossman, M. Taylor Pyne Professor emeritus of Romance Languages at Princeton University, is the author of books on Edward Gibbon, Augustin Thierry, Jacob Burckhardt, J.J. Bachofen, and the eighteenth-century French m..
Impact des anticorps antiphospholipides sur l’hypertension artérielle et le devenir rénal dans la néphropathie lupique classe III/IV
No full textObjectives: to determine in lupus nephritis (LN) patients having an antiphospholipid syndrome (APS) but no superadded APS nephropathy, the arterial hypertension (AH) incidence and renal outcome. Methods: a retrospective monocenter study was conducted from 1999 to 2017. All patients (n=124) with a biopsy-proven LN class III/IV were included. Four superadded APS nephropathies were excluded, and 3 groups were then defined: without aPL (LN), with aPL but no clinical manifestation (LN+aPL), with APS (LN+APS). Data concerning blood pressure (BP), antihypertensive therapy (AHT), estimated glomerular filtration rate (eGFR) and end-stage renal failure (ESRF) were recorded at baseline, 1-year, 5-years and end of follow-up. Results: we retrospectively observed 78 LN (63%), 23 LN+ aPL (18.5%) and 23 LN+APS (18.5%). The mean follow-up time was 7.5 ±4.5 years for LN, 7.6 ±4.7 years for LN+aPL and 8.8 ±4.6 years for LN+APS (p=0.4). There was no difference of BP levels between the 3 groups throughout the study. At the end of follow-up, the proportion of patients without AHT was significantly lower in LN+APS (41%, 42%, and 24%, p=0.02), but eGFR, slope of eGFR and ESRF rate were similar between the 3 groups (eGFR [p=0.9], slope of eGFR [p=0.06], ESRF [p=0.5]). Conclusion: in LN patients having an APS but no superadded APS nephropathy, more AHT is required to obtain normal BP. Long term-renal outcome is good in these patients.Objectif : déterminer dans la néphropathie lupique (NL) classe III/IV l’incidence de l’hypertension artérielle (HTA) et le devenir rénal en cas de syndrome des antiphospholipides secondaire (SAPL) sans néphropathie aux antiphospholipides (NAPL). Méthodes : une étude rétrospective monocentrique a été réalisée sur la période de 1999 à 2017. Tous les patients (n=124) avec une néphropathie lupique classe III/IV prouvée par biopsie étaient inclus, 4 NAPL ont été exclus et 3 groupes ont été définis : sans anticorps antiphospholipides (aPL) (NL), avec aPL mais sans manifestation clinique (NL+aPL), et avec un SAPL (NL+APS). Les données relatives à la tension artérielle (TA), aux traitements antihypertenseurs, le débit estimé de filtration glomérulaire (DFG), la pente de DFG et la nécessité d'un traitement de suppléance rénale ont été recueillies à l'inclusion, à 1 an, 5 ans et à la fin du suivi. Résultats : notre cohorte était composée de 78 NL (61 %), 23 NL+aPL (18,5 %) and 23 NL+APS (18,5 %). Le temps de suivi moyen était de 7.5 ±4.5 années pour les NL, 7.6 ±4.7 années pour les NL+aPL et 8.8 ±4.6 années pour les NL+APS (p=0.4). Il n'y avait pas de différence significative de TA entre les 3 groupes à tous les temps de l'étude. A la fin du suivi, la proportion de patients sans traitement antihypertenseur était significativement moins importante dans le groupe NL+APS (41 %, 42 %, et 24 %, p=0.02), mais le DFG, la pente de DFG et le taux d'insuffisance rénale stade V étaient similaires dans les 3 groupes. (DFG [p=0.9], pente de DFG [p=0.06], traitement de suppléance [p=0.5]. Conclusion : parmi les patients atteints de NL, ceux présentant un SAPL nécessitent plus de traitements antihypertenseurs afin d'obtenir un contrôle tensionnel adéquate. Le pronostic rénal est similaire aux autres NL
- …
